Targeting podoplanin for the treatment of osteosarcoma

CONCLUSIONS: Targeting PDPN with a neutralizing antibody against PDPN-CLEC-2 without ADCC and CDC is a novel therapeutic strategy for PDPN-positive OS.PMID:35381070 | DOI:10.1158/1078-0432.CCR-21-4509

Source: Clinical Cancer Research - April 5, 2022 Category: Cancer & Oncology Authors: Ai Takemoto Satoshi Takagi Takao Ukaji Nobuhiko Gyobu Mamoru Kakino Miho Takami Asami Kobayashi Marie Lebel Tokuichi Kawaguchi Minoru Sugawara Kazue Tsuji-Takayama Kenji Ichihara Yuki Funauchi Keisuke Ae Seiichi Matsumoto Yoshiya Sugiura Kengo Takeuchi Te Source Type: research